Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.

Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.

Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.

And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.

And Treeline and HengRui also get in on the pan-RAS act.

Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.